Profound Medical (NASDAQ:PROF – Get Free Report) and Aptorum Group (NASDAQ:APM – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.
Earnings & Valuation
This table compares Profound Medical and Aptorum Group”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Profound Medical | $10.68 million | 21.17 | -$27.82 million | ($1.34) | -4.65 |
| Aptorum Group | $430,000.00 | 12.58 | -$4.27 million | N/A | N/A |
Analyst Recommendations
This is a breakdown of current ratings for Profound Medical and Aptorum Group, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Profound Medical | 1 | 0 | 1 | 0 | 2.00 |
| Aptorum Group | 1 | 0 | 0 | 0 | 1.00 |
Profound Medical presently has a consensus price target of $12.00, indicating a potential upside of 92.62%. Given Profound Medical’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Profound Medical is more favorable than Aptorum Group.
Risk & Volatility
Profound Medical has a beta of 0.6, meaning that its stock price is 40% less volatile than the S&P 500. Comparatively, Aptorum Group has a beta of 0.11, meaning that its stock price is 89% less volatile than the S&P 500.
Profitability
This table compares Profound Medical and Aptorum Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Profound Medical | -275.16% | -86.18% | -70.55% |
| Aptorum Group | N/A | N/A | N/A |
Institutional and Insider Ownership
47.9% of Profound Medical shares are owned by institutional investors. Comparatively, 3.8% of Aptorum Group shares are owned by institutional investors. 1.5% of Profound Medical shares are owned by company insiders. Comparatively, 64.0% of Aptorum Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Summary
Profound Medical beats Aptorum Group on 7 of the 12 factors compared between the two stocks.
About Profound Medical
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
About Aptorum Group
Aptorum Group Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for the treatment of infectious diseases and cancer. The company operates in the Therapeutics and Non-Therapeutics segments. Its pipeline products include SACT- 1 for neuroblastoma and other cancer types; SACT-COV19 for the treatment of coronavirus disease; ALS-4 to treat bacterial infections caused by staphylococcus aureus, including MRSA; and ALS-1 to treat viral infections caused by influenza virus A. The company is also developing ALS-2/3 for the treatment of gram+ve bacterial infections; RPIDD, a pathogen molecular diagnostic; NativusWell DOI (NLS-2), a dietary supplement; NLS-1 for the treatment of endometriosis; DLS-1+2 to treat NSCLC with mutation; DLS-3, an autoimmune small molecule; and CLS-1 for the treatment of obesity. Its pipeline products enable the discovery of new therapeutics assets, such as systematic screening of existing approved drug molecules, and microbiome-based research platforms for treatment of metabolic diseases. The company also focuses on therapeutic and diagnostic projects in neurology, gastroenterology, metabolic disorders, women's health, and other disease areas. In addition, it operates a medical clinic. The company was formerly known as APTUS Holdings Limited and changed its name to Aptorum Group Limited in October 2017. Aptorum Group Limited was incorporated in 2010 and is headquartered in London, the United Kingdom. Aptorum Group Limited is a subsidiary of Jurchen Investment Corporation.
Receive News & Ratings for Profound Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Profound Medical and related companies with MarketBeat.com's FREE daily email newsletter.
